<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01037348</url>
  </required_header>
  <id_info>
    <org_study_id>CRFB002AGB10</org_study_id>
    <secondary_id>2009-014854-14</secondary_id>
    <nct_id>NCT01037348</nct_id>
  </id_info>
  <brief_title>Ranibizumab for the Treatment of Choroidal Neovascularisation (CNV) Secondary to Pathological Myopia (PM): an Individualized Regimen</brief_title>
  <acronym>REPAIR</acronym>
  <official_title>A Phase II, Open-label, Multicentre, 12 Month Study to Evaluate the Efficacy and Safety of Ranibizumab (0.5mg) in Patients With Choroidal Neovascularisation Secondary to Pathological Myopia (PM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study is designed to provide efficacy and safety data in patients with choroidal&#xD;
      neovascularisation (CNV) secondary to myopia using an individualized as-needed (PRN) dosing&#xD;
      schedule. Eligible patients who have provided written agreement to take part in the study&#xD;
      will receive an intravitreal (into the study eye) injection of ranibizumab 0.5mg. Following&#xD;
      eye examinations and tests at monthly clinic visits, the study doctor will repeat the&#xD;
      injections on a monthly basis as required for an additional 11 months, in accordance with&#xD;
      specified retreatment criteria.&#xD;
&#xD;
      Patients will be in the study for approximately 12 months and will visit the hospital clinic&#xD;
      14 times over that period. The main assessments will include visual acuity tests, eye&#xD;
      examinations, optical coherence tomography (OCT) to assess retinal thickness, fundus&#xD;
      photography and fluorescein angiography (FA), measurement of intraocular pressure, blood&#xD;
      pressure and pulse measurements and completion of health-related questionnaires'.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The difference from baseline in mean Best Corrected Visual Acuity (BCVA)</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change in BCVA from baseline</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in Central retinal Thickness (CRT) from baseline</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients gaining ≥ 15 letters</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lesion size and morphology from baseline</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to the first retreatment and the total number of treatments</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Choroidal Neovascularisation</condition>
  <arm_group>
    <arm_group_label>ranibizumab 0.5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ranibizumab 0.5mg</intervention_name>
    <arm_group_label>ranibizumab 0.5mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female outpatients of any race, aged 18 years or older&#xD;
&#xD;
          -  Diagnosis of active primary or recurrent subfoveal or juxtafoveal CNV secondary to PM&#xD;
&#xD;
          -  Diagnosis of high myopia of at least -6 dioptres in the study eye spherical&#xD;
             equivalent. For subjects who have undergone prior refractive or cataract surgery in&#xD;
             the study eye, the preoperative refractive error in the study eye must have been at&#xD;
             least -6 dioptres&#xD;
&#xD;
          -  Patients who have a BCVA score between 78 and 24 letters in the study eye using Early&#xD;
             Treatment Diabetic Retinopathy Study (ETDRS)-like grading charts (approximately 6/9 -&#xD;
             6/96 Snellen equivalent)&#xD;
&#xD;
          -  Patients must give fully informed consent and be willing and able to comply with all&#xD;
             study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of any surgical intervention in the study eye within two months preceding&#xD;
             screening&#xD;
&#xD;
          -  Previous macular laser photocoagulation, treatment with intravitreal steroids,&#xD;
             verteporfin with photodynamic therapy (Visudyne®) or anti-VEGF agents ranibizumab,&#xD;
             bevacizumab or pegaptanib sodium (Macugen®) in the study eye&#xD;
&#xD;
          -  Previous treatment with intravenously administered bevacizumab (Avastin®)&#xD;
&#xD;
          -  Prior treatment in the study eye with external-beam radiation therapy, vitrectomy, or&#xD;
             transpupillary thermotherapy&#xD;
&#xD;
          -  History of hypersensitivity to any of the study drugs or to drugs of similar chemical&#xD;
             classes&#xD;
&#xD;
          -  History of allergic reaction to fluorescein&#xD;
&#xD;
          -  Concurrent use of systemic anti-VEGF agents&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bristol</city>
        <zip>BS1 2LX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site</name>
      <address>
        <city>City of London</city>
        <zip>EC1V 2PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>City of London</city>
        <zip>NW1 5YE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>City of London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frimley</city>
        <zip>GU16 7UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Torquay</city>
        <zip>TQ2 7AA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wolverhampton</city>
        <zip>WV10 0QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>York</city>
        <zip>YO31 8HE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <study_first_submitted>December 21, 2009</study_first_submitted>
  <study_first_submitted_qc>December 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2009</study_first_posted>
  <last_update_submitted>April 15, 2016</last_update_submitted>
  <last_update_submitted_qc>April 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Choroidal Neovascularisation</keyword>
  <keyword>Pathological Myopia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myopia</mesh_term>
    <mesh_term>Choroidal Neovascularization</mesh_term>
    <mesh_term>Myopia, Degenerative</mesh_term>
    <mesh_term>Neovascularization, Pathologic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

